New findings identify familial Alzheimer's mutations in the SORLA receptor as disruptors of neurotrophic exosome release, reducing cell-to-cell messaging critical for brain health and advancing disease progression. Additional research implicates ABCA7—a lipid transporter gene variant—increased Alzheimer’s risk through altered neuronal lipid metabolism. Furthermore, Remynd’s therapeutic work restores neuronal calcium homeostasis to reduce tau pathology. These multifaceted discoveries deepen molecular understanding of Alzheimer’s and open avenues for targeted interventions.